Topadur Pharma

News

8.10.20

Interview with Reto Naef, CEO of TOPADUR PHARMA AG

Read the full interview:

Download Document Dokument herunterladen Switzerland Global Enterprise Switzerland Global Enterprise

9.11.22

News

Scientific Publication in Pharmaceutics

Topical Wound Treatment with a NO-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.

7.4.22

Press Release

TOPADUR in collaboration with USZ / UZH was awarded CHF 605k by Innosuisse

Pulmonary fibrosis is a chronic and usually fatal disease. The project will investigate the anti-fibrotic effects of TOP-V122.

6.7.21

Press Release

TOPADUR Pharma AG announces completion of TOP-N53 First-in-Man Study

TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.